Targeted protein degradation (TPD) stands as a revolutionary technology capable of selectively eliminating specific proteins of interest by leveraging natural cellular processes, including the ubiquitin-proteasome and lysosome pathways. This innovative approach has dramatically broadened our arsenal of drug modalities, enabling us to address molecular targets previously deemed "undruggable," particularly by small molecule drugs. The field of TPD is rapidly expanding and has emerged as a primary focus not only within the biopharmaceutical industry but also in academic research. Notably, technologies like PROTAC (Proteolysis-Targeting Chimeras) and molecular glues utilizing the ubiquitin-proteasome pathway have transitioned swiftly from academic labs to biotechnology companies, poised to become an common tool for medicinal chemists. Meanwhile, methods targeting membrane proteins for degradation, such as LYTAC (Lysosome Targeting Chimeras), are still in their early stages.